Translating Best Evidence into Best Care

EDITOR’S NOTE: Studies for this issue were identified using the Clinical Queries feature of PubMed, “hand” searching JAMA Pediatrics, Pediatrics, and The Journal of Pediatrics, and from customized EvidenceUpdates alerts.

EBM PEARL: THE META-ANALYSIS I² STATISTIC: A primary meta-analysis validity issue is combining studies that are measuring the same outcome in the same way. At times, individual study results may vary considerably. This variability may be due to clinical and methodological study differences. The I² statistic was developed to measure outcome variability among the individual studies. The higher the variability (heterogeneity), the more likely the individual studies are insufficiently similar and therefore should not be combined. As a general rule, an I² <40% suggests homogeneity, which supports study combination. Larger values represent a higher likelihood of heterogeneity and suggest that meta-analysis may not be warranted. An example of how the I² is used in a meta-analysis is shown in the piece by Zhang on page 221 regarding the article by Brooks et al (JAMA Pediatr 2016;170:577-84).

LITERATURE SEARCH PEARL: SUMSEARCH 2: SUMSearch 2 (http://sumsearch.org), developed by Dr Robert Badgett, is a free, University of Kansas-based meta-search engine designed to perform multiple searches at one time, employing a number of other Internet-based medical-literature search engines, and collating the results in one place. The SUMSearch 2 standard 6 search iterations enhance the search quality, retrieving the most methodologically sound studies, and grouping them by original studies, systematic reviews, and guidelines. SUMSearch 2 also displays current medical news and ClinDx (clindx.wordpress.com), a blog that highlights studies that compute clinical exam diagnostic test statistics.

—Jordan Hupert, MD

Hypertonic saline for bronchiolitis – a meta-analysis reanalysis


Question Among hospitalized infants with bronchiolitis, what is the therapeutic efficacy of hypertonic saline (HS), compared with placebo, in reducing length of stay (LOS)?

Design Re-analysis of 2 meta-analyses of randomized controlled studies.

Setting Hospitals worldwide.

Participants Mean age <9 months.

Intervention HS versus placebo.

Outcomes LOS and study heterogeneity as measured by the I² statistic.

Main Results Two main sources of heterogeneity were identified. Controlling, either for one study population with a widely divergent primary outcome definition, or, for divergent, between-treatment-groups prepresentation mean day of illness (DOI), resolved the heterogeneity: I² reduced from 78% to 45% and 0%, respectively, and produced nonsignificant summary estimates (ie, HS does not affect LOS).

Conclusions An outlier population and unbalanced treatment groups confounded previous HS meta-analyses’ results.

Commentary The substantial heterogeneity of LOS could be expected given the variation across trials in definition of acute bronchiolitis, disease severity, standard care, intervention regimen, outcome measures and risk of bias. This and other recently published systematic reviews have explored such potential heterogeneity sources.1-3 One of the main sources of heterogeneity identified by this review was the outlier results of two trials from the same group in China. These two trials used more stringent discharge criteria and had longer LOS in the control groups. Another main source of heterogeneity identified by this review was an imbalance in the mean DOI at presentation between treatment groups. However, caution should be taken in interpreting this finding. First, a difference of 0.5-day in DOI is an arbitrary cut-off for classifying subgroups. Any changes in the cut-off value may substantially affect the results of analysis. Second, it does not seem reasonable to combine, into the same subgroup, five trials that did not report DOI, two trials with a group difference of ≥0.5 day in DOI, and three trials with a balanced DOI. Given that neither individual trials nor pooled estimates from systematic reviews could definitively confirm or deny the potential benefits of HS in acute bronchiolitis, large international multicenter trials are still warranted.

Linjie Zhang, MD, PhD
Federal University of Rio Grande
Rio Grande, Brazil

References

Abscess drainage with and without antibiotics


**Question** Among children with an uncomplicated abscess, what is the therapeutic efficacy of trimethoprim-sulfamethoxazole (TMPS) compared with placebo, in abscess resolution?

**Design** Multicenter, randomized, controlled trial.

**Setting** Outpatient clinic.

**Participants** Patients, 14-73 years old of age with a drainable abscess.

**Intervention** Drainage plus TMPS or placebo.

**Outcomes** Abscess resolution 7-14 days following treatment.

**Main Results** The absolute risk reduction for abscess resolution with TMPS was 6.9% (95% CI, 2.1%-11.7%), number needed to treat, 15 (95% CI, 9-48). Antibiotic treatment was also associated with statistically significant lower rates of subsequent surgical drainage (3.4% vs 8.6%), new skin infections (3.1% vs 10.3%), and infections of household members (1.7% vs 4.1%).

**Conclusions** TMPS use improved cure rates compared with drainage alone.

**Commentary** Historically, uncomplicated skin-abscess first-line treatment has been surgical drainage, resulting in resolution in approximately 80% of cases. Treatment with antibiotics, both compared with drainage alone and concomitant drainage plus antibiotics, has not been previously shown to improve cure rates. However, many of these studies were performed prior to increasing rates of community acquired MRSA and limited by small patient populations. The current study by Talan et al, which is both well-designed and adequately powered, provides new evidence as to the efficacy of adjuvant antibiotic treatment of skin abscesses. These results should be interpreted with caution, as a significant number of abscesses (73.6%) were cured with drainage alone. Improvements in cure rate, new infections, and repeat drainage were modest. Gastrointestinal side effects of antibiotics treatment were mild and there were no serious adverse events, such as *Clostridium difficile* colitis or Stevens Johnson syndrome. This study, in conjunction with another study, suggests the cost-benefit ratio for antibiotics in the treatment of soft tissue infections may be changing.

James Antoon, MD, PhD
University of Illinois at Chicago
Chicago, Illinois

---

**Antibiotic treatment of appendicitis**


**Question** Among children with nonperforated appendicitis, what is the therapeutic efficacy of antibiotic treatment, compared with prompt appendectomy, in resolving appendicitis?

**Design** Meta-analysis of randomized trials.

**Setting** Europe.

**Participants** Children, young adults, and adults, 5-75 years old.

**Intervention** Antibiotic treatment versus prompt appendectomy.

**Outcomes** Complications and appendicitis relapse.

**Main Results** No difference in complication rate. Within 1 year, appendicitis recurred in 114 of 510 patients in the antibiotic group: pooled estimate 22.6% (95% CI, 15.6% to 30.4%), number needed to recur: 5 (95% CI, 4 to 6).

**Conclusions** Nonperforated appendicitis antibiotic treatment is a value- and preference-based decision.

**Commentary** This meta-analysis is meticulously performed and introduces both Grading of Recommendations Assessment, Development and Evaluation for assessing the quality of evidence, and the Clavien-Dindo classification for stratification of complications. Surprisingly, there are now more meta-analyses published than randomized controlled trials, and even a review of the meta-analyses. All meta-analyses include a different combination of studies but come to fairly similar conclusions, raising the question of the benefit of yet another meta-analysis. That said, this meta-analysis provides the best presented, and probably best quality data to present to the individual patient for shared decision-making. Still, long-term outcome data are needed to reach a final conclusion regarding the benefit of the nonoperative approach to acute appendicitis. My personal opinion is that the antibiotics-first, appendectomy-when-needed treatment strategy of nonperforated acute appendicitis in children is valid in cases where surgery, and general anesthesia, would mean an increased risk (eg, post gastrochisis, omphalocoele, or other previous major abdominal surgery, ongoing airway infection, and in patients with cystic fibrosis). Apart from this, nonoperative treatment should not routinely be performed outside the framework of a randomized controlled trial.

---

**References**

Benefits of late parenteral nutrition in critically ill children


**Question** Among critically ill children, what is the therapeutic efficacy of early versus late parenteral nutrition (PN), in infection rates and duration of need for pediatric intensive care unit (PICU) care?

**Design** Multicenter, randomized, controlled trial.

**Setting** PICUs in Belgium, the Netherlands, and Canada.

**Participants** Critically ill children requiring PN.

**Intervention** Early (within 24 hours) verses late (starting on the 8th day) PN.

**Outcomes** New infection rate and duration of need for PICU care.

**Main Results** Children receiving late PN had fewer new infections, number needed to treat (NNT) 13 (95% CI, 9-24), and less PICU-level care (>1week), NNT 8 (95% CI, 6-11).

**Conclusions** Providing critically ill children PN only after 1 week was clinically superior to early nutrition.

**Commentary** The Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit (PEPaNIC) Study was a 3-center trial that compared early (within 24 hours) versus late (day 8) supplemental PN in the PICU population. The patient selection criteria and the unique PN strategies limit the external validity of this elegant study. Early or late PN strategy was randomly allocated to patients who tolerated early enteral nutrition with stepwise advancement, but were unable to reach 80% of the energy goal within 24 hours of admission. Most US centers do not routinely practice the aggressive PN strategy in the early group. Furthermore, only a fraction of patients in the late arm received any PN. The energy goals were equation-estimated in 2 of the 3 sites, with potential for underfeeding and overfeeding. Based on the PEPaNIC Study results, the routine use of PN within 24 hours of PICU admission cannot be recommended. These results cannot be extrapolated to severely malnourished patients, low birth weight newborns, and those ineligible for any enteral nutrition. These vulnerable groups were inadequately represented in the study and may not benefit from prolonged nutrient deprivation. Individualized macronutrient goals and emphasis on the enteral route with selective and cautious PN use might be prudent in the PICU.

**References**


Asthma and cesarean delivery


**Question** Among otherwise well children, what is the association of asthma with cesarean delivery?

**Design** Data analysis of 2 prospective birth cohorts.

**Setting** Copenhagen, Denmark.

**Participants** Children born to mothers with asthma.

**Intervention** Cesarean delivery.

**Outcomes** Asthma risk by delivery mode.

**Main Results** The asthma rate was increased by cesarean delivery, adjusted hazard ratio, 2.18 (95% CI, 1.27-3.73). Delivery performed prior to membrane rupture carried a significantly higher risk of asthma, incidence rate ratio, 1.20 (95% CI, 1.16-1.23), compared with cesarean delivery after membrane rupture, incidence rate ratio, 1.12 (95% CI, 1.09-1.16).

**Conclusions** Cesarean delivery, especially with intact membranes, is associated with childhood asthma.

**Commentary** Unmeasured maternal or familial factors resulting in cesarean birth before rupture of membranes and asthma could underlie these fascinating observations. A similar registry-based study from Sweden found a higher risk of asthma for cesarean births, but not for elective cesareans after accounting for such factors by comparing siblings. Cesarean birth before membrane rupture also had lower gestational age, associated with both poorer lung function and asthma, possibly with a dose response to 40 weeks, but not fully accounted for by adjusting for grouped gestational age. Re-analysis using a fully adjusted sibling design would illuminate whether exposing cesarean-birth, preruptured membranes to the maternal vaginal microbiome might prevent asthma.

C. Mary Schooling, PhD
City University of New York
New York, New York

The University of Hong Kong
Hong Kong, China
References
